New Glioblastomas Findings from Xuzhou Medical University Described (FBXO22 promotes glioblastoma malignant progression by mediating VHL ubiquitination and degradation).

A study conducted by researchers at Xuzhou Medical University explores the role of FBXO22 in glioblastoma (GBM), the most common malignant primary brain tumor. The study found that FBXO22 is highly expressed in glioma and is associated with worse pathological features and shorter survival in GBM patients. FBXO22 promotes GBM cell proliferation, angiogenesis, migration, and tumorigenesis by decreasing VHL expression, which increases HIF-1a and VEGFA expression. The researchers suggest that FBXO22 could serve as a diagnostic marker and therapeutic target for glioma patients. [Extracted from the article]